Table 1.

Clinicopathologic characteristics of HHLA2 expression in patients with lung cancers from the discovery and validation cohorts

Discovery cohort (n = 392)Validation cohort (n = 287)
ParameterHHLA2 NegativeHHLA2 PositivePParameterHHLA2 NegativeHHLA2 PositiveP
Age, year67.967.50.78Age, year70.5700.47
Gender0.60Gender0.09
 Female (n = 215)78 (36%)137 (64%) Female (n = 180)46 (26%)134 (74%)
 Male (n = 141)55 (39%)86 (61%) Male (n = 80)29 (36%)51 (64%)
Race0.06Race
 Asia (n = 7)4 (57%)3 (43%) N/A
 AA* (n = 18)8 (44%)10 (56%)
 Hispanic (n = 25)16 (64%)9 (36%)
 White (n = 230)87 (38%)143 (62%)
Histology<0.0001Histology0.92
 Adeno (n = 290)91 (31%)199 (69%) Adeno (n = 186)58 (31%)128 (69%)
 Squam (n = 31)20 (65%)11 (35%) Squam (n = 29)8 (27%)21 (73%)
 Large (n = 18)16 (89%)2 (11%) Large (n = 3)1 (33%)2 (67%)
Stage0.09Stage0.39
 I (n = 252)85 (34%)167 (66%) I (n = 157)43 (27%)114 (73%)
 II (n = 47)23 (49%)24 (51%) II (n = 39)15 (38%)24 (61%)
 III (n = 35)10 (29%)25 (71%) III (n = 22)7 (31%)15 (69%)
Lymph node (N per TNM staging)0.35Lymph node (N per TNM staging)0.94
 N0 (n = 259)94 (32%)165 (64%) N0 (n = 177)50 (28%)127 (72%)
 N1 (n = 35)14 (40%)21 (60%) N1 (n = 27)7 (26%)20 (74%)
 N2 (n = 26)6 (23%)20 (77%) N2 (n = 20)6 (30%)14 (70%)
Mutation status0.04Mutation status0.01
 EGFR (n = 41)10 (24%)31 (76%) EGFR(n = 44)5 (11%)39 (89%)
 KRAS (n = 62)23 (37%)39 (63%) KRAS (n = 66)24 (36%)42 (64%)
 WT/WT (n = 91)43 (47%)48 (53%) WT/WT (n = 88)27 (31%)61 (69%)
TIL score0.26TIL score0.03
 Absent (n = 13)3 (23%)10 (77%) Absent (n = 24)6 (25%)18 (75%)
 Low (n = 238)94 (40%)144 (60%) Low (n = 191)63 (33%)128 (67%)
 High (n = 108)35 (32%)73 (68%) High (n = 44)6 (14%)38 (86%)